ASX Filings

Opthea Provides Timing Update on OPT-302 Clinical Trials

July 22, 2019

Change in substantial holding

June 4, 2019

Opthea Completes Final Patient Visit in Phase 2b Wet AMD Clinical Trial

May 15, 2019

Additional Formats

PDF Version

Appendix 3B

April 12, 2019

Change of Director's Interest Notice - MB

April 5, 2019

Change of Director's Interest Notice - MB

March 19, 2019

Change of Director's Interest Notice - MS

March 19, 2019

Appendix 3B

March 19, 2019

Change of Director's Interest Notice - GK

March 19, 2019

Opthea Added to the S&P/ASX All Ordinaries Index

March 18, 2019